Garm adds Klotho to cell and gene therapy platform in Roatan
Garm LLC, operating as Longevity Advanced, has launched an expanded longevity therapies platform featuring non-permanent plasmid gene therapies, including Klotho, alongside previously utilized follistatin and VEGF. This initiative, spearheaded by orthopedic surgeon Dr. Glenn C. Terry, is based at the Garm Clinic in Roatan, Honduras, and aims to address age-related decline by enhancing mitochondrial, cellular, and organ function.
The inclusion of Klotho is particularly noteworthy, as it targets mechanisms associated with inflammation, oxidative stress, and metabolic aging. By promoting mineral metabolism and insulin sensitivity, this therapy could significantly impact how we approach age-related health challenges. Additionally, the VEGF plasmid therapy, which has already treated over 30,000 patients for critical limb ischemia, underscores the platform’s potential for broad clinical applications.
This development signals a shift towards personalized longevity protocols that do not involve permanent genetic alterations, offering a new avenue for patients seeking innovative solutions to enhance their healthspan.